An Update on Malignant Melanoma Vaccine ResearchInsights into Mechanisms for Improving the Design and Potency of Melanoma Therapeutic Vaccines

被引:0
作者
Stephen John Ralph
机构
[1] Griffith University,School of Medical Science
来源
American Journal of Clinical Dermatology | 2007年 / 8卷
关键词
Melanoma; Melanoma Cell; Metastatic Melanoma; Ipilimumab; Cancer Vaccine;
D O I
暂无
中图分类号
学科分类号
摘要
Currently, cancer vaccine therapy for melanoma has a 2-fold focus. On the one hand, advances have been aimed at improving the effectiveness of melanoma vaccines based on a greater understanding of melanoma tumor cell biology. On the other hand, there is increasing evidence that the immune system, our defense against tumors, also inadvertently plays a supportive role in promoting the development and progression of tumors. Hence, two opposing forces ‘hanging in the balance’ dictate patients’ responses to melanoma: tumor cell biology and the status of the immune system. Recent developments in our understanding of both of these aspects have provided new leads and insights for novel ways to improve vaccine design and add to the melanoma vaccine armory. As the focus of immunotherapy shifts its aim towards the tumor microenvironment, we are now developing the ability to program the immune responses raised by vaccination against melanoma. The aim here is to prevent myeloid and regulatory T-cell-mediated immune suppression as well as to counteract tumor-derived factors capable of suppressing immune responses. A redirected strategy for vaccine immunotherapy is proposed based on our greater understanding of tumor immunity. Using a combination therapy of immune-potentiating melanoma vaccines together with adjuvants for overcoming the immunosuppressive forces will allow us to activate protective immunity against melanoma. Other cancer vaccines (i.e. colon or renal) are already offering reasons for hope and expectation that vaccine immunotherapy will also produce successful outcomes for patients with melanoma.
引用
收藏
页码:123 / 141
页数:18
相关论文
共 576 条
  • [1] Dezfouli S(2005)Use of cytokines in cancer vaccines/ immunotherapy: recent developments improve survival rates for patients with metastatic malignancy Curr Pharm Des 11 3511-30
  • [2] Hatzinisiriou I(2005)Melanoma vaccines: what we know so far Oncology (Williston Park) 19 97-108
  • [3] Ralph SJ(2006)The treatment of melanoma with an emphasis on immunotherapeutic strategies Surg Oncol 15 13-24
  • [4] Bystryn JC(2006)Evaluation of immunotherapy in the treatment of melanoma Surg Oncol Clin N Am 15 399-418
  • [5] Reynolds SR(2006)Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations Clin Cancer Res 12 2331-6
  • [6] Jack A(2006)Allogeneic and autologous melanoma vaccines: where have we been and where are we going Clin Cancer Res 12 2337-41
  • [7] Boyes C(2006)Update on immunotherapy for melanoma J Natl Compr Canc Netw 7 687-94
  • [8] Aydin N(2004)Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes Proc Natl Acad Sci U S A 101 14639-45
  • [9] Faries MB(2005)Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma J Clin Oncol 23 2346-57
  • [10] Kirkwood JM(2006)Adoptive immunotherapy for cancer: building on success Nat Rev Immunol 6 383-93